Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors.

Trial Profile

Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Vorolanib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Tyrogenex
  • Most Recent Events

    • 08 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017, according to ClinicalTrials.gov record.
    • 18 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 May 2014 Planned End Date changed from 1 Jun 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top